CET

Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease at the SSIEM Annual Symposium

Retrieved on: 
Tuesday, August 30, 2022

The data will be presented on August 31, 2022, at the annual symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) in Freiburg, Germany.

Key Points: 
  • The data will be presented on August 31, 2022, at the annual symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) in Freiburg, Germany.
  • The first patients data from the RESKUE clinical trial demonstrate that intravenous FBX-101 following UCBT has been safe and well tolerated through Day 180.
  • Notably, the data demonstrate an absence of humoral immune response against the vector and significantly increased GALC enzyme activity.
  • Through Day 180, the patient exhibited improved motor activity and normal brain development compared to previously reported transplanted patients with Krabbe disease.

Galapagos receives transparency notification from FMR LLC

Retrieved on: 
Monday, August 29, 2022

Mechelen, Belgium; 29 August 2022, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.

Key Points: 
  • Mechelen, Belgium; 29 August 2022, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.
  • Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 25 August 2022 from FMR LLC, who notified that it holds 3,710,782 of Galapagos voting rights, consisting of 3,710,782 ordinary shares.
  • FMR LLC controls investment funds Fidelity Management & Research Company LLC, FIAM Holdings LLC, Fidelity Management Trust Company and Strategic Advisers LLC, of which Fidelity Management & Research Company LLC decreased its position to 3,272,828 voting rights, and Strategic Advisers LLC increased its position to 10,322 voting rights.
  • FMR LLC's holding of 3,710,782 Galapagos' voting rights, including its controlled undertakings holdings, represents 5.65% of Galapagos' currently outstanding 65,728,511 shares.

FREYR Battery Invites to a Press Meeting

Retrieved on: 
Monday, August 29, 2022

FREYR Battery (NYSE: FREY) (FREYR), a developer of clean, next-generation battery cell production capacity, will conduct a press meeting at ONS Stavanger in Hall 10 on Tuesday, August 30 at 8:00 am CET (02:00 am EST).

Key Points: 
  • FREYR Battery (NYSE: FREY) (FREYR), a developer of clean, next-generation battery cell production capacity, will conduct a press meeting at ONS Stavanger in Hall 10 on Tuesday, August 30 at 8:00 am CET (02:00 am EST).
  • View the full release here: https://www.businesswire.com/news/home/20220829005685/en/
    Press meeting streamed FREYR Battery (Photo: Business Wire)
    A webcast of the press conference call will be broadcast simultaneously at https://vimeo.com/743463440 on a listen-only basis.
  • To register your physical attendance at the press conference at ONS, please contact: [email protected]
    FREYR Battery aims to provide industrial scale clean battery solutions to reduce global emissions.
  • FREYR intends to install 50 GWh of battery cell capacity by 2025 and 100 GWh annual capacity by 2028 and 200 GWh of annual capacity by 2030.

Tartisan Nickel Corp. Files Preliminary Economic Assessment of the Kenbridge Nickel Project, Northwestern Ontario, on SEDAR

Retrieved on: 
Monday, August 29, 2022

Toronto, Ontario--(Newsfile Corp. - August 29, 2022) - Tartisan Nickel Corp. (CSE: TN) (OTCQX: TTSRF) (FSE: 8TA) ("Tartisan", or the "Company") is pleased to announce the completion and filing of the Preliminary Economic Assessment ("PEA") for the 100% owned Kenbridge Nickel Project, Northwestern Ontario (SEDAR August 26, 2022).

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - August 29, 2022) - Tartisan Nickel Corp. (CSE: TN) (OTCQX: TTSRF) (FSE: 8TA) ("Tartisan", or the "Company") is pleased to announce the completion and filing of the Preliminary Economic Assessment ("PEA") for the 100% owned Kenbridge Nickel Project, Northwestern Ontario (SEDAR August 26, 2022).
  • This PEA is focused solely on underground mining of the Mineral Resources at the Kenbridge Nickel Project and provides a solid base case for moving the Kenbridge Nickel Project forward.
  • Mark Appleby President and CEO of Tartisan states: "The Kenbridge Nickel Project PEA is focused solely on the current underground Mineral Resource.
  • Additional information about Tartisan Nickel Corp. can be found at the Company's website at www.tartisannickel.com or on SEDAR at www.sedar.com .

Pixium Vision announces participation in upcoming scientific conferences in September 2022

Retrieved on: 
Monday, August 29, 2022

Paris, France, August 29, 2022 07:00 CET Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that senior management will participate in the following scientific conferences during September 2022:

Key Points: 
  • Paris, France, August 29, 2022 07:00 CET Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that senior management will participate in the following scientific conferences during September 2022:
    Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.
  • Pixium Visions bionic vision systems are associated with a surgical intervention and a rehabilitation period.
  • Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD).
  • The company is EN ISO 13485 certified and qualifies as Entreprise Innovante by Bpifrance.

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

Retrieved on: 
Friday, August 26, 2022

The data, which are the first data with BCX9930 in patients with C3G, are being presented in a poster session at the 18th European Meeting on Complement in Human Disease, which is being held in Bern, Switzerland, from August 26-29, 2022.

Key Points: 
  • The data, which are the first data with BCX9930 in patients with C3G, are being presented in a poster session at the 18th European Meeting on Complement in Human Disease, which is being held in Bern, Switzerland, from August 26-29, 2022.
  • The analyses found that a single oral dose (600 mg) of BCX9930:
    Demonstrated >99 percent (median) suppression of the AP, and that >98 percent (median) suppression was maintained for 24 hours post-dosing, in C3G patients.
  • Achieved rapid (within two hours) and maximal (median >99 percent relative to pre-dose levels) suppression of the generation of C3a, a product of C3 convertase activity, in both healthy volunteers and C3G patients.
  • Currently, BioCryst is conducting the RENEW proof-of-concept basket study evaluating BCX9930 in C3G, immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN), all rare renal diseases caused by dysregulation of the alternative pathway.

Sofwave™ to Showcase SUPERB™ (Synchronous Ultrasound Parallel Beam Technology) Live and In-Person at 5CC International Aesthetic Medical and Dermatology Conference

Retrieved on: 
Thursday, August 25, 2022

5CC is an international boutique industry conference focused on medical dermatology injectables for aesthetic & medical use cosmetic & aesthetic energy-based systems aesthetic gynecology practice management & digital marketing.

Key Points: 
  • 5CC is an international boutique industry conference focused on medical dermatology injectables for aesthetic & medical use cosmetic & aesthetic energy-based systems aesthetic gynecology practice management & digital marketing.
  • For more information about the conference please visit the main page of the conference website here: LINK .
  • Sofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction and lifting using proprietary breakthrough technology.
  • Synchronous Ultrasound Parallel Beam technology is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin) and neck tissue providing physicians with smart yet simple, effective, and safe aesthetic solutions for their patients.

DGAP-News: tonies delivers very strong performance in the first half-year with continued momentum in international markets and confirms guidance for full-year 2022

Retrieved on: 
Thursday, August 25, 2022

This performance was driven across all channels as we successfully continued to execute our growth strategy, including an ongoing strong brand build-up.

Key Points: 
  • This performance was driven across all channels as we successfully continued to execute our growth strategy, including an ongoing strong brand build-up.
  • Overall, the regional share of revenues outside of DACH increased from 9% in H1 2021 to 25% in H1 2022.
  • tonies confirms its guidance with expected revenue of EUR 250 million for the group and of EUR 52 million for the US.
  • tonies employs over 300 people and has been listed on the Frankfurt stock exchange through tonies SE since 2021.

Galapagos to present at upcoming investor conferences

Retrieved on: 
Wednesday, August 24, 2022

Mechelen, Belgium; 24 August 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that management will participate in the following upcoming investor conferences:

Key Points: 
  • Mechelen, Belgium; 24 August 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that management will participate in the following upcoming investor conferences:
    Citis 17th Annual Biopharma Conference.
  • September 8, 2022 in Boston
    Morgan Stanley 20thGlobal Healthcare Conference.
  • September 12-14, 2022 in New York
    Bank of America Merrill Lynch Global Healthcare Conference.
  • September 15, 2022 in London
    KBC Securities Virtual Life Sciences Conference.

Maxon Gears Up for the Return to IBC Show 2022 in Amsterdam

Retrieved on: 
Wednesday, August 24, 2022

FRIEDRICHSDORF, Germany, Aug. 24, 2022 /PRNewswire-PRWeb/ -- Maxon, developer of professional 3D software solutions for editors, filmmakers, motion designers and visual effects artists, is pleased to announce that they will be showcasing their Maxon One product line in-person on stand 7.A27 at the 2022 IBC Show in Amsterdam from September 9th-12th. Having demonstrated these tools for the first time altogether at NAB 2022, IBC offers yet another opportunity for attendees to see the impressive collection that makes up the Maxon toolkit. In addition to the product showcase, a host of talented digital artists will share their workflow tips and tricks live. These presentations will also be streaming live via the 3D and Motion Design Show each day of the show.

Key Points: 
  • Having demonstrated these tools for the first time altogether at NAB 2022, IBC offers yet another opportunity for attendees to see the impressive collection that makes up the Maxon toolkit.
  • In addition to the product showcase, a host of talented digital artists will share their workflow tips and tricks live.
  • "We are looking forward to the industry's return to IBC and we're certainly aiming to come back with a bang.
  • Presentations will also be available on demand shortly after airing on 3DMotionShow.com , as well as the Maxon YouTube channel .